ALLOGENEIC BONE-MARROW TRANSPLANTATION FOLLOWING BUSULFAN AND 90 MG KG OF CYCLOPHOSPHAMIDE/

Ten patients with AML or CML aged 40-55 years underwent allogeneic mar row transplantation from HLA-identical siblings following a preparatio n regimen of busulfan 16mg/kg and cyclophosphamide (CY) 90mg/kg. The C Y dose was substantially lower than has been previously used in combin ation with busulfan. All 10 individuals engrafted. Cytogenetic analysi s of marrow and peripheral blood cells demonstrated similar patterns o f chimerism to those previously described using higher CY doses. This study demonstrates that when administered with busulfan 16mg/kg a dose of 90mg/kg CY is adequately immunosuppressive to permit consistent en graftment of marrow from HLA-indentical sibling donors.